Increasing length of hormone therapy reduces breast cancer recurrence, study finds

Futile Cancer Treatment

Researchers on Saturday reported about the results of the largest study to date of a new blood test that can detect and analyze cancer.

United Kingdom trial lead Dr. Sara Erridge, consultant oncologist at the Edinburgh Cancer Centre, said: "Our important study showed that giving temozolomide chemotherapy after radiotherapy delays progression and significantly improves survival for this group of patients".

The findings show that about a quarter of individuals diagnosed with lung cancer have autoimmune conditions, which means that about 20 to 50 million patients in the USA will be excluded as immunotherapy treatments for cancer become more widely used. A total of 133 bone fractures occurred among women assigned letrozole, compared with 88 in the placebo arm.

The most common autoimmune diseases reported were rheumatoid arthritis, psoriasis, and polymyalgia rheumatica.

"'In general, I would think that women who had riskier cancers, higher stage. would look to these data and think they are compelling for continuing longer durations of treatment".

"It could also help prevent the rare occurrence of cancer being diagnosed in the other breast".

"Since the use of cancer immunotherapy is growing, examining the effectiveness and toxicity of these promising treatments among patients with autoimmune diseases will be critical", said Dr. Gerber, Co-Director of UT Southwestern's Experimental Therapeutics Program, which aims to identify novel targets for tumor targeting, perform laboratory testing of new treatment strategies, and develop new biomarkers and clinical trials.

He believes the real value of liquid biopsy will show itself as a patient's cancer treatment proceeds.

Dr. Ali Riza Sever, one of the researchers at the University of Hacettepe's oncology centre, told the BBC News website: "It tells us obesity is an adverse factor when it comes to chemotherapy before surgery".

"There's very often regret from the patient's loved ones, who not uncommonly say, 'If I had known it was going to be like this, we never would have wanted this, '" he said.

ASCO's annual meeting is considered the premier education and scientific event in the clinical cancer research community.



Related News: